Free Trial

Jazz Pharmaceuticals (JAZZ) Stock Forecast & Price Target

Jazz Pharmaceuticals logo
$111.43
+2.02 (+1.85%)
(As of 11/5/2024 ET)

Jazz Pharmaceuticals - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
3
Buy
11

Based on 14 Wall Street analysts who have issued ratings for Jazz Pharmaceuticals in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 14 analysts, 3 have given a hold rating, and 11 have given a buy rating for JAZZ.

Consensus Price Target

$173.43
55.64% Upside
According to the 14 analysts' twelve-month price targets for Jazz Pharmaceuticals, the average price target is $173.43. The highest price target for JAZZ is $230.00, while the lowest price target for JAZZ is $113.00. The average price target represents a forecasted upside of 55.64% from the current price of $111.43.
Get the Latest News and Ratings for JAZZ and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Jazz Pharmaceuticals and its competitors.

Sign Up

JAZZ Analyst Ratings Over Time

TypeCurrent Forecast
11/6/23 to 11/5/24
1 Month Ago
10/7/23 to 10/6/24
3 Months Ago
8/8/23 to 8/7/24
1 Year Ago
11/6/22 to 11/6/23
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
11 Buy rating(s)
11 Buy rating(s)
12 Buy rating(s)
6 Buy rating(s)
Hold
3 Hold rating(s)
3 Hold rating(s)
4 Hold rating(s)
1 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$173.43$173.14$175.20$206.67
Forecasted Upside55.64% Upside58.29% Upside56.08% Upside55.63% Upside
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy

JAZZ Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

JAZZ Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Jazz Pharmaceuticals Stock vs. The Competition

TypeJazz PharmaceuticalsMedical CompaniesS&P 500
Consensus Rating Score
2.79
2.79
2.50
Consensus RatingModerate BuyModerate BuyHold
Predicted Upside58.51% Upside16,384.14% Upside10.48% Upside
News Sentiment Rating
Positive News

See Recent JAZZ News
Neutral News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
10/23/2024Royal Bank of Canada
4 of 5 stars
 Boost TargetOutperform ➝ Outperform$175.00 ➝ $179.00+60.58%
9/10/2024Needham & Company LLC
2 of 5 stars
 Reiterated RatingBuy ➝ Buy$205.00 ➝ $205.00+92.56%
9/9/2024Cantor Fitzgerald
3 of 5 stars
 Reiterated RatingOverweight ➝ Overweight$140.00 ➝ $140.00+30.57%
8/19/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$190.00 ➝ $202.00+79.33%
8/1/2024Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight ➝ Overweight$188.00 ➝ $166.00+44.16%
8/1/2024Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetEqual Weight ➝ Equal Weight$140.00 ➝ $120.00+6.52%
8/1/2024HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Buy$200.00 ➝ $200.00+81.41%
8/1/2024Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform ➝ Outperform$160.00 ➝ $154.00+39.68%
7/12/2024Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetEqual Weight ➝ Equal Weight$160.00 ➝ $150.00+40.85%
7/2/2024UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetNeutral ➝ Neutral$117.00 ➝ $113.00+7.28%
6/5/2024The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$169.00+61.75%
5/3/2024Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight ➝ Overweight$230.00 ➝ $200.00+83.65%
3/20/2024Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Buy$200.00+60.88%
3/15/2024Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$225.00 ➝ $230.00+87.04%
9/28/2023Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageMarket Perform
8/10/2023Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$204.00 ➝ $217.00+60.74%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 08:37 PM ET.


JAZZ Forecast - Frequently Asked Questions

According to the research reports of 14 Wall Street equities research analysts, the average twelve-month stock price forecast for Jazz Pharmaceuticals is $173.43, with a high forecast of $230.00 and a low forecast of $113.00.

14 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Jazz Pharmaceuticals in the last year. There are currently 3 hold ratings and 11 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" JAZZ shares.

According to analysts, Jazz Pharmaceuticals's stock has a predicted upside of 55.64% based on their 12-month stock forecasts.

Jazz Pharmaceuticals has been rated by research analysts at Cantor Fitzgerald, JPMorgan Chase & Co., Needham & Company LLC, and Royal Bank of Canada in the past 90 days.

Analysts like Jazz Pharmaceuticals less than other "medical" companies. The consensus rating score for Jazz Pharmaceuticals is 2.79 while the average consensus rating score for "medical" companies is 2.79. Learn more on how JAZZ compares to other companies.


This page (NASDAQ:JAZZ) was last updated on 11/5/2024 by MarketBeat.com Staff
From Our Partners